We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...

In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...